CancerNetwork®
@CancerNetwrk
Followers
30K
Following
4K
Media
4K
Statuses
22K
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
Cranbury, NJ
Joined February 2009
📢 Calling all radiation oncologists! We’re launching a peer-reviewed, PubMed-indexed #radonc supplement in 2026, and are accepting submissions. ✨Introducing @brandonmancini of @bamfhealth and @UMich as our editor-at-large. 👉Find out how to submit and get published today:
0
8
13
PFS was significantly improved when 177Lu-PNT2002 was added to stereotactic body radiotherapy for patients with oligorecurrent hormone-sensitive prostate cancer. https://t.co/zgubU5xCOA
#pcsm #cancer #oncology
cancernetwork.com
In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.
0
0
0
Use of PEG hydrogels significantly reduced radiation to the rectum without increasing dosage to other organs at risk in patients undergoing radical concurrent chemoradiotherapy for cervical cancer. https://t.co/QuKRD95t01
#gyncsm #oncology #cancer
cancernetwork.com
Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.
0
0
0
HRQOL scores were similar in patients who received a radical cystectomy vs bladder persevering therapy for non-muscle invasive bladder cancer. https://t.co/4H6f08ibA9
#NMIBC #blcsm #oncology
cancernetwork.com
HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.
0
0
0
The FDA has granted traditional approval to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor. https://t.co/o76qD9lcw4
#lymsm #leusm #oncology | @FDAOncology
0
0
0
Subcutaneous toripalimab plus chemotherapy exhibited noninferior drug exposure compared with toripalimab injection in metastatic or recurrent nonsquamous NSCLC. https://t.co/J0gTH4173h
#NSCLC #lcsm #oncology
cancernetwork.com
The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.
0
0
1
Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC. https://t.co/iCZbdH1Tle
#pcsm #cancer #oncology
0
0
0
Final results from HERIZON-BTC-01 showed zanidatamab achieved a cORR of 41.3%, with a DOR of 14.9 months, in biliary tract cancer. https://t.co/CwLQZimatv
#cancer #oncology #biliary
cancernetwork.com
Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.
0
0
1
Updated 5-year results from the phase 2 JULIET trial showed that the ORR with tisa-cel was 53.0%, with 39.1% of patients having a best overall response of CR. Read the full article here: https://t.co/v2HdhTGq9L
#lymsm #lymphoma #oncology
cancernetwork.com
ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.
0
0
0
According to John Henson, MD, patients with ovarian, breast, endometrial, and colon cancers benefit the most from proactive hereditary analyses. Read the full conversation here: https://t.co/rXIAwojV7x
#btsm #cancer #oncology | @GACancerCenter
cancernetwork.com
According to John Henson, MD, patients with ovarian, breast, endometrial, and colon cancers benefit the most from proactive hereditary analyses.
0
1
1
Beyond just the physical aspect of cancer treatment, the logistical, financial, and emotional burdens caused by treatment significantly impacts patients. We spoke with @GreenupRachel about these considerations. Read here: https://t.co/npFHd28bNo
#bcsm #cancer #oncology
cancernetwork.com
According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.
0
0
0
The number of oncologists qualified to treat the aging US population is declining! 🎙️ We spoke with the authors of the eye-opening study 🎥 Read the transcript here: https://t.co/aL5NF5iWUf
#cancer #oncology | @MAccordino | @ASCO
cancernetwork.com
A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.
0
0
0
FDA grants Priority Review for sonrotoclax in relapsed/refractory MCL (post-BTKi). Phase 1/2 data showed the BCL2 inhibitor met its ORR endpoint. Full data due at #ASH25. https://t.co/G0Xe1OX7nm
#lymsm #MCL #Hematology #Oncology
cancernetwork.com
The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.
0
0
0
The FDA has approved an updated label for cosibelimab-ipdl for adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are ineligible to receive curative surgery or radiation. https://t.co/kMqSSZQOXl
#cancer #oncology
0
0
1
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care, according to @guicorreiamd. Watch more here: https://t.co/JroR2NDGTW
#lcsm #oncology #cancer
cancernetwork.com
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
0
0
0
When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD, and Yesne Alici, MD, utilize several decision-making capacity techniques. Read more here: https://t.co/nNMgIRknOP
#cancer #oncology
cancernetwork.com
When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD; and Yesne Alici, MD, will utilize decision-making capacity techniques.
0
0
1
“What we need are better treatments to control the [brain] tumor once it’s detected," said John Henson, MD. Watch here: https://t.co/fL6Jbf7JsN
#btsm #cancer #oncology | @GACancerCenter
cancernetwork.com
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
0
1
1
PAS-004 achieved positive PD, PK, and safety results in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1, or RAF mutation, or in those in which prior BRAF/MEK inhibition had failed patients. https://t.co/4ACNZYKBhx
#cancer #oncology
cancernetwork.com
PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.
0
0
0
Priming strategies with olaparib, including the addition of durvalumab with or without low-dose cyclophosphamide, did not definitively improve efficacy outcomes vs olaparib monotherapy in platinum-sensitive recurrent ovarian cancer. https://t.co/VFcZWtkNxj
#cancer
cancernetwork.com
Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.
0
1
0
The FDA has granted FTD to AVZO-103, an investigational Nectin4/TROP2 bispecific ADC, for adults with locally advanced or metastatic urothelial cancer following prior receipt of enfortumab vedotin. https://t.co/ESnkC3nMY9
#cancer #oncology
0
0
0
🏥 Real-World Data From IMS: Outpatient/Hybrid Step-Up Dosing in RRMM In episode 5 of this Between the Lines series, experts, Binod Dhakal, MD, MS, and Hans Lee, MD, reveal that new data shows that outpatient or hybrid dosing of Teclistamab can be safe, effective, and
0
0
0